Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2007 1
2010 1
2011 1
2012 2
2013 5
2014 7
2015 4
2016 6
2017 5
2018 2
2019 5
2020 6
2021 8
2022 5
2023 8
2024 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK; STAMPEDE investigators. James ND, et al. Lancet. 2016 Mar 19;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5. Epub 2015 Dec 21. Lancet. 2016. PMID: 26719232 Free PMC article. Clinical Trial.
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
Parker CC, Kynaston H, Cook AD, Clarke NW, Catton CN, Cross WR, Petersen PM, Persad RA, Pugh CA, Saad F, Logue J, Payne H, Bower LC, Brawley C, Rauchenberger M, Barkati M, Bottomley DM, Brasso K, Chung HT, Chung PWM, Conroy R, Falconer A, Ford V, Goh CL, Heath CM, James ND, Kim-Sing C, Kodavatiganti R, Malone SC, Morris SL, Nabid A, Ong AD, Raman R, Rodda S, Wells P, Worlding J, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 Jun 1;403(10442):2416-2425. doi: 10.1016/S0140-6736(24)00549-X. Epub 2024 May 16. Lancet. 2024. PMID: 38763153 Free PMC article. Clinical Trial.
Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study.
Papa S, Adami A, Metoudi M, Beatson R, George MS, Achkova D, Williams E, Arif S, Reid F, Elstad M, Beckley-Hoelscher N, Douri A, Delord M, Lyne M, Shivapatham D, Fisher C, Hope A, Gooljar S, Mitra A, Gomm L, Morton C, Henley-Smith R, Thavaraj S, Santambrogio A, Andoniadou C, Allen S, Gibson V, Cook GJR, Parente-Pereira AC, Davies DM, Farzaneh F, Schurich A, Guerrero-Urbano T, Jeannon JP, Spicer J, Maher J. Papa S, et al. Among authors: guerrero urbano t. J Immunother Cancer. 2023 Jun;11(6):e007162. doi: 10.1136/jitc-2023-007162. J Immunother Cancer. 2023. PMID: 37321663 Free PMC article.
In Regard to Reber et al.
Humbert-Vidan L, Patel V, King AP, Guerrero Urbano T. Humbert-Vidan L, et al. Among authors: guerrero urbano t. Adv Radiat Oncol. 2023 Jul 14;8(4):101222. doi: 10.1016/j.adro.2023.101222. eCollection 2023 Jul-Aug. Adv Radiat Oncol. 2023. PMID: 37465003 Free PMC article. No abstract available.
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Parker CC, Clarke NW, Cook AD, Kynaston H, Catton CN, Cross WR, Petersen PM, Persad RA, Saad F, Bower LC, Logue J, Payne H, Forcat S, Goldstein C, Murphy C, Anderson J, Barkati M, Bottomley DM, Branagan J, Choudhury A, Chung PWM, Cogley L, Goh CL, Hoskin P, Khoo V, Malone SC, Masters L, Morris SL, Nabid A, Ong AD, Raman R, Tarver KL, Tree AC, Worlding J, Wylie JP, Zarkar AM, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 Jun 1;403(10442):2405-2415. doi: 10.1016/S0140-6736(24)00548-8. Epub 2024 May 16. Lancet. 2024. PMID: 38763154 Free PMC article. Clinical Trial.
Protocol Letter: A multi-institutional retrospective case-control cohort investigating PREDiction models for mandibular OsteoRadioNecrosis in head and neck cancer (PREDMORN).
Humbert-Vidan L, Hansen CR, Fuller CD, Petit S, van der Schaaf A, van Dijk LV, Verduijn GM, Langendijk H, Muñoz-Montplet C, Heemsbergen W, Witjes M, Mohamed ASR, Khan AA, Marruecos Querol J, Oliveras Cancio I, Patel V, King AP, Johansen J, Guerrero Urbano T. Humbert-Vidan L, et al. Among authors: guerrero urbano t. Radiother Oncol. 2022 Nov;176:99-100. doi: 10.1016/j.radonc.2022.09.014. Epub 2022 Sep 28. Radiother Oncol. 2022. PMID: 36179801 Free PMC article. No abstract available.
Assessing the quality of patient-reported outcome measurements for gynecological cancers: a systematic review.
Moss CL, Guerrero-Urbano T, White I, Taylor B, Kristeleit R, Montes A, Fox L, Beyer K, Sztankay M, Ratti MM, Sisca ES, Derevianko A, MacLennan S, Wood N, Wintner LM, Van Hemelrijck M. Moss CL, et al. Among authors: guerrero urbano t. Future Oncol. 2023 Mar;19(9):663-678. doi: 10.2217/fon-2022-0111. Epub 2023 May 2. Future Oncol. 2023. PMID: 37128990 Review.
61 results